Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

计划入组 183 人 · 首次发布于 2005 年 11 月 23 日

Phase I trial of YHI-1003

计划入组 18 人

Phase II trial of YHI-1003

计划入组 96 人

PHP-1003

KER-1003

GQ-1003

103 Hospital

Vietnam

HAN BIOMEDICAL INC.

Taiwan

HBN GROUP PTY LTD

Australia

Earendil Labs and Genentech Sign Bispecific Antibody Collaboration Worth More Than $1.5 Billion

Earendil Labs Initiates Phase IIa Trial of Half-Life Extended Anti-TL1A Antibody HXN-1001 for Ulcerative Colitis

Sarepta Advances SRP-1003 siRNA Therapy for Myotonic Dystrophy Type 1 with Positive Safety Review